August 2015 Australian Public Assessment Report for Insulin glargine
Yüklə 1,57 Mb.
|
- Bu səhifədəki naviqasiya:
- August 2015 Australian Public Assessment Report for Insulin glargine
- About the Therapeutic Goods Administration (TGA)
- About AusPARs
- Contents List of the most common abbreviations used in this AusPAR 4 I. Introduction to product submission 5
- III. Nonclinical findings 9
- V. Pharmacovigilance findings 23
- Attachment 1. Product Information 39 Attachment 2. Extract from the Clinical Evaluation Report 39
About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. To report a problem with a medicine or medical device, please see the information on the TGA website About AusPARs An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. AusPARs are prepared and published by the TGA. An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA. Copyright © Commonwealth of Australia 2015 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to Contents List of the most common abbreviations used in this AusPAR 4 I. Introduction to product submission 5 Submission details 5 Product background 5 Regulatory status 7 Product information 7
Drug substance (active ingredient) 7 Drug product 8 Biopharmaceutics 8 Quality summary and conclusions 9
Introduction 9 Pharmacology 9 Pharmacokinetics 10 Toxicology 10 Nonclinical summary and conclusions 11 IV. Clinical findings 11 Introduction 11 Clinical rationale 11 Guidance 12 Contents of the clinical dossier 13 Pharmacokinetics 13 Pharmacodynamics 16 Dosage selection for the pivotal studies 17 Efficacy 17 Safety 18 First round benefit-risk assessment 22 First round recommendation regarding authorisation 22 Clinical questions 22 Second round evaluation of clinical data submitted in response to questions 22 V. Pharmacovigilance findings 23 Risk management plan 23 VI. Overall conclusion and risk/benefit assessment 28 Quality 28 Nonclinical 28 Clinical 29 Risk management plan 34 Risk-benefit analysis 34 Outcome 38 Attachment 1. Product Information 39 Attachment 2. Extract from the Clinical Evaluation Report 39 List of the most common abbreviations used in this AusPAR
Yüklə 1,57 Mb. Dostları ilə paylaş:
|